Additionally, specific symptom improvement seen
WEDNESDAY, April 9, 2025 (HealthDay News) — Prescribing medical cannabis to patients with chronic health conditions may improve health-related quality of life (HRQL), as well as some specific symptoms such as pain, fatigue, insomnia, anxiety, and depression, according to a study published online April 2 in PLOS ONE.
Margaret-Ann Tait, from the University of Sydney, and colleagues assessed overall HRQL, pain, fatigue, sleep, anxiety, depression, and motor function in a large real-world sample of patients prescribed medicinal cannabis. The analysis included 2,353 participants with follow-up data.
The researchers found that chronic conditions commonly treated were musculoskeletal pain (38.1 percent), neuropathic pain (23.2 percent), insomnia (23.2 percent), anxiety (22.1 percent), and mixed depressive and anxiety disorder (11.2 percent). There were clinically meaningful improvements in HRQL, patient-reported fatigue, and sleep disturbance. For participants diagnosed with chronic pain, there were clinically meaningful improvements in scores for patient-reported pain intensity and patient-reported pain interference. For those with mental health conditions, there was significant improvement in Depression Anxiety and Stress Scale anxiety and depression, but there were no motor function improvements observed for participants with movement disorders.
“Statistically significant and clinically meaningful improvements in overall HRQL, fatigue, and sleep disturbance were maintained over 12 months in patients prescribed medical cannabis for chronic health conditions,” the authors write. “Anxiety, depression, insomnia, and pain also improved over time for those with corresponding health conditions.”
Several authors disclosed ties to relevant organizations.
Actigraphy Measures of Sleep, Activity Linked to Depression Relapse
Risk Factors Identified for Irritable Bowel Syndrome in Young Adulthood
TBI Linked to Elevated Transition Probabilities to Work Disability
Use of Meds for Mental Health Up in Children, Young Adults From 2001 to 2020
Oxybutynin Beats Placebo for Reducing ADT-Linked Hot Flashes in Prostate Cancer
Sodium-Glucose Cotransporter 2 Inhibitors Tied to Lower Use of Gout Medications
Secondary Cardiovascular Disease Prevention With Semaglutide at Cash Price Is Cost-Effective
Motor Activities Linked to Psychosocial QoL in Older Adults With Osteoarthritis